These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium. Gerlier L, Lamotte M, Dos Santos Mendes S, Damm O, Schwehm M, Eichner M. Paediatr Drugs; 2016 Aug; 18(4):303-18. PubMed ID: 27272706 [Abstract] [Full Text] [Related]
4. Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands. de Boer PT, Nagy L, Dolk FCK, Wilschut JC, Pitman R, Postma MJ. Value Health; 2021 Jan; 24(1):19-31. PubMed ID: 33431149 [Abstract] [Full Text] [Related]
7. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model. Crépey P, Boiron L, Araujo RR, Lopez JG, Petitjean A, de Albuquerque Luna EJ. BMC Public Health; 2020 Sep 09; 20(1):1374. PubMed ID: 32907562 [Abstract] [Full Text] [Related]
8. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States. Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ. Vaccine; 2008 Jun 02; 26(23):2841-8. PubMed ID: 18462851 [Abstract] [Full Text] [Related]
9. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Ryan J, Zoellner Y, Gradl B, Palache B, Medema J. Vaccine; 2006 Nov 17; 24(47-48):6812-22. PubMed ID: 17034909 [Abstract] [Full Text] [Related]
11. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model. Yang MC, Tan EC, Su JJ. Hum Vaccin Immunother; 2017 Jan 02; 13(1):81-89. PubMed ID: 27624648 [Abstract] [Full Text] [Related]
12. Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives. de Fougerolles TR, Baïssas T, Perquier G, Vitoux O, Crépey P, Bartelt-Hofer J, Bricout H, Petitjean A. BMC Public Health; 2024 May 03; 24(1):1222. PubMed ID: 38702667 [Abstract] [Full Text] [Related]
13. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA. Hum Vaccin Immunother; 2014 May 03; 10(5):1171-80. PubMed ID: 24609063 [Abstract] [Full Text] [Related]
14. Direct and Indirect Protection with Pediatric Quadrivalent Live-Attenuated Influenza Vaccination in Europe Estimated by a Dynamic Transmission Model. Gerlier L, Hackett J, Lawson R, Dos Santos Mendes S, Weil-Olivier C, Schwehm M, Eichner M. J Health Econ Outcomes Res; 2017 May 03; 5(1):89-108. PubMed ID: 37664688 [Abstract] [Full Text] [Related]
16. Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany. Molnar D, Anastassopoulou A, Poulsen Nautrup B, Schmidt-Ott R, Eichner M, Schwehm M, Dos Santos G, Ultsch B, Bekkat-Berkani R, von Krempelhuber A, Van Vlaenderen I, Van Bellinghen LA. Hum Vaccin Immunother; 2022 Nov 30; 18(5):2058304. PubMed ID: 35486410 [Abstract] [Full Text] [Related]
17. Vaccination of children with a live-attenuated, intranasal influenza vaccine - analysis and evaluation through a Health Technology Assessment. Andersohn F, Bornemann R, Damm O, Frank M, Mittendorf T, Theidel U. GMS Health Technol Assess; 2014 Nov 30; 10():Doc03. PubMed ID: 25371764 [Abstract] [Full Text] [Related]
18. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population. Capri S, Barbieri M, de Waure C, Boccalini S, Panatto D. Hum Vaccin Immunother; 2018 Jun 03; 14(6):1331-1341. PubMed ID: 29425079 [Abstract] [Full Text] [Related]